Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Lassa Fever Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Lassa Fever Overview | 8 | 1 |
| Pipeline Products for Lassa Fever Comparative Analysis | 9 | 1 |
| Lassa Fever Therapeutics under Development by Companies | 10 | 1 |
| Lassa Fever Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Lassa Fever Pipeline Products Glance | 12 | 1 |
| Early Stage Products | 12 | 1 |
| Lassa Fever Products under Development by Companies | 13 | 1 |
| Lassa Fever Products under Investigation by Universities/Institutes | 14 | 1 |
| Lassa Fever Companies Involved in Therapeutics Development | 15 | 6 |
| Arno Therapeutics, Inc. | 15 | 1 |
| Celgene Corporation | 16 | 1 |
| Etubics Corporation | 17 | 1 |
| Kineta, Inc. | 18 | 1 |
| Profectus BioSciences, Inc. | 19 | 1 |
| SIGA Technologies, Inc. | 20 | 1 |
| Lassa Fever Therapeutics Assessment | 21 | 9 |
| Assessment by Monotherapy Products | 21 | 1 |
| Assessment by Target | 22 | 2 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Drug Profiles | 30 | 20 |
| AR-12 Drug Profile | 30 | 3 |
| CC-11050 Drug Profile | 33 | 1 |
| DEF-201 Drug Profile | 34 | 2 |
| FBH-003 Drug Profile | 36 | 1 |
| FDX-000 Drug Profile | 37 | 1 |
| KIN-1400 Drug Profile | 38 | 1 |
| lassa fever vaccine Drug Profile | 39 | 1 |
| lassa fever vaccine Drug Profile | 40 | 1 |
| lassa fever vaccine 1 Drug Profile | 41 | 1 |
| lassa fever vaccine 2 Drug Profile | 42 | 1 |
| LHF-535 Drug Profile | 43 | 1 |
| Monoclonal Antibodies for Lassa Fever Drug Profile | 44 | 1 |
| Monoclonal Antibodies for Viral Infections Drug Profile | 45 | 2 |
| Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus Drug Profile | 47 | 1 |
| ST-193 Drug Profile | 48 | 2 |
| Lassa Fever Dormant Projects | 50 | 1 |
| Lassa Fever Product Development Milestones | 51 | 2 |
| Featured News &Press Releases | 51 | 1 |
| May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials | 51 | 1 |
| Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals | 51 | 1 |
| May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research | 52 | 1 |
| Appendix | 53 | 2 |
| Methodology | 53 | 1 |
| Coverage | 53 | 1 |
| Secondary Research | 53 | 1 |
| Primary Research | 53 | 1 |
| Expert Panel Validation | 53 | 1 |
| Contact Us | 53 | 1 |
| Disclaimer | 54 | 1 |